A Randomized Phase 2 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - "POPLAR"
Public ClinicalTrials.gov record NCT01903993. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II, Open-label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of MPDL3280A (Anti-PD-L1 Antibody) Compared With Docetaxel in Patients With Non-Small Cell Lung Cancer After Platinum Failure
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This multicenter, open-label, randomized study will evaluate the efficacy and safety of Atezolizumab compared with docetaxel in participants with advanced or metastatic non-small cell lung cancer after platinum failure. Participants will be randomized to receive either Atezolizumab 1200 milligram (mg) intravenously every 3 weeks or docetaxel 75 milligram per meter square (mg/m\^2) intravenously every 3 weeks. Treatment with Atezolizumab may be continued as long as participants are experiencing clinical benefit as assessed by the investigator, i.e., in the absence of unacceptable toxicity or symptomatic deterioration attributed to disease progression.
Study identification
- NCT ID
- NCT01903993
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 287 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 6, 2013 (Actual)
- Primary completion
- Nov 19, 2015 (Actual)
- Completion
- Sep 6, 2018 (Actual)
- Last update posted
- Oct 2, 2019
2013 – 2018
United States locations
- U.S. sites
- 29
- U.S. states
- 19
- U.S. cities
- 29
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arizona Oncology Associates, PC - HOPE | Tucson | Arizona | 85704 | — |
| Genesis Cancer Center | Hot Springs | Arkansas | 71913 | — |
| Loma Linda University Medical Center | Loma Linda | California | 92354 | — |
| Kaiser Permanente - San Marcos | San Marcos | California | 92069 | — |
| Kaiser Permanente - Vallejo | Vallejo | California | 94589 | — |
| Innovative Clinical Research Institute | Whittier | California | 90603 | — |
| Rocky Mountain Cancer Centers - Colorado Springs (Circle) | Lone Tree | Colorado | 80124 | — |
| Ocala Oncology Center | Ocala | Florida | 34471 | — |
| Georgia Cancer Specialists | Atlanta | Georgia | 30341 | — |
| Ingalls Memorial Hospital | Harvey | Illinois | 60426 | — |
| Illinois Cancer Care | Peoria | Illinois | 61615 | — |
| New England Cancer Specialists | Scarborough | Maine | 04074 | — |
| Karmanos Cancer Institute.. | Detroit | Michigan | 48201 | — |
| Billings Clinic; Research Center | Billings | Montana | 59101 | — |
| Comprehensive Cancer Centers of Nevada - Eastern Avenue | Las Vegas | Nevada | 89169 | — |
| The Valley Hospital | Paramus | New Jersey | 07652 | — |
| New York Oncology Hematology, P.C. | Albany | New York | 12206 | — |
| Broome Oncology - Binghamton | Binghamton | New York | 13905 | — |
| Willamette Valley Cancer Ctr - 520 Country Club | Eugene | Oregon | 97401-8122 | — |
| Rhode Island Hospital | Providence | Rhode Island | 02903 | — |
| Center for Biomedical Research LLC | Knoxville | Tennessee | 37909 | — |
| Texas Oncology - South Austin | Austin | Texas | 78745 | — |
| Texas Oncology, P.A. - Fort Worth | Fort Worth | Texas | 76104 | — |
| Virginia Cancer Specialists, PC | Fairfax | Virginia | 22031 | — |
| Virginia Oncology Associates | Norfolk | Virginia | 23502 | — |
| Blue Ridge Cancer Care | Roanoke | Virginia | 24014 | — |
| Northwest Cancer Specialists - Vancouver | Vancouver | Washington | 98684 | — |
| Providence St. Mary Regional Cancer Center | Walla Walla | Washington | 99362 | — |
| Wenatchee Valley Hospital & Clinics | Wenatchee | Washington | 98801 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 36 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01903993, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 2, 2019 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01903993 live on ClinicalTrials.gov.